The future of EU HTA

What will change in drug assessment as of 2025

The roadmap to a new process

In 2021, the adoption of the legislation for joint European Health Technology Assessment (EU HTA) initiated a new era for HTA. As of 2025, cancer and advanced therapy medicinal products will need to be assessed through a pan-EU lens.

While all stakeholders agree that pan-EU collaboration on HTA and harmonization of processes and requirements is valuable, the shift to a mandatory process leaves some open questions:

What does HTA mean at the EU level?
What are key concerns about the new process?
How can you prepare for the future of EU HTA?

Download our latest whitepaper to help answer these questions and better prepare for the implementation of a pan-EU HTA.

Please enter your details to download our latest whitepaper. If you would like to continue the conversation with an IQVIA expert, please check the box below.

First Name*

Last Name*

Email Address*

Title*

Company*

Country*

I would like to speak to an IQVIA expert*

Yes

If yes, please provide us with more detail of your need.

Opt In

By selecting this box, I consent to receiving marketing communications and information about IQVIA's offering by email.

address1

DO NOT SELL MY PERSONAL INFORMATION